20,490 Shares in Progyny, Inc. (NASDAQ:PGNY) Acquired by Bryce Point Capital LLC

Bryce Point Capital LLC acquired a new stake in shares of Progyny, Inc. (NASDAQ:PGNY) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 20,490 shares of the company’s stock, valued at approximately $353,000.

Several other large investors have also made changes to their positions in PGNY. Charles Schwab Investment Management Inc. boosted its holdings in Progyny by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,446 shares of the company’s stock valued at $11,287,000 after purchasing an additional 4,007 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Progyny by 227.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 789,418 shares of the company’s stock valued at $13,231,000 after buying an additional 548,602 shares during the period. State Street Corp boosted its stake in shares of Progyny by 4.5% in the third quarter. State Street Corp now owns 3,113,654 shares of the company’s stock worth $52,185,000 after buying an additional 134,861 shares during the last quarter. Wolverine Trading LLC grew its holdings in Progyny by 131.5% during the third quarter. Wolverine Trading LLC now owns 19,677 shares of the company’s stock worth $331,000 after acquiring an additional 11,177 shares during the period. Finally, Wellington Management Group LLP raised its position in Progyny by 4.0% during the third quarter. Wellington Management Group LLP now owns 430,300 shares of the company’s stock valued at $7,212,000 after acquiring an additional 16,638 shares in the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. BTIG Research raised shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price objective on the stock in a research note on Monday, March 31st. Canaccord Genuity Group raised their price target on shares of Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, February 28th. JPMorgan Chase & Co. upped their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Finally, Bank of America raised their target price on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $23.64.

Progyny Stock Down 2.4 %

PGNY stock opened at $22.60 on Friday. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $36.36. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of 38.97, a price-to-earnings-growth ratio of 2.39 and a beta of 1.33. The business has a fifty day moving average of $22.19 and a two-hundred day moving average of $18.54.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.